News

QT Activity: Medical Device Approval in Australia – What You Need to Know in 2025 Webinar Recap – April/May 2025

QT Activity: Medical Device Approval in Australia – What You Need to Know in 2025 Webinar Recap – April/May 2025

  • 2025-04-24 09:48:40

On March 26, 2025, Qualtech hosted a regulatory webinar exploring the process of medical device approval in Australia. The session covered essential topics including device classification, conformity assessment options, ARTG registration steps, sponsor and manufacturer obligations, post-market surveillance, and upcoming UDI requirements. Practical tips and FAQs helped attendees better prepare for TGA submissions and long-term compliance in the Australian market.

More
Australia: Breakthrough in Cardiac Transplants: The Future of Artificial Hearts – April/May 2025

Australia: Breakthrough in Cardiac Transplants: The Future of Artificial Hearts – April/May 2025

  • 2025-04-24 10:18:36

The Total Artificial Heart (TAH) project, supported by a hefty AUD50 million investment from the Australian Government, is poised to redefine the future of cardiac care. As it progresses into the stage of human trials, the TAH could potentially serve as a viable long-term solution to heart transplants, thereby establishing Australia as a global leader in the fight against cardiovascular diseases.

More
Australia: Understanding TGA's New Requirements for Medical Devices Containing Medicinal, Microbial, Recombinant, or Animal-Origin Substances – April/May 2025

Australia: Understanding TGA's New Requirements for Medical Devices Containing Medicinal, Microbial, Recombinant, or Animal-Origin Substances – April/May 2025

  • 2025-04-24 03:49:40

The Therapeutic Goods Administration (TGA) has introduced updated regulatory requirements, effective from July 1, 2024, for medical devices containing medicinal, microbial, recombinant, or animal-origin substances. These changes aim to streamline classification rules, update labelling requirements, and broaden the recognition of international regulatory approvals, thereby reducing unnecessary regulatory burdens while maintaining safety standards.

More
Australia: Unique Device Identification (UDI) Requirements: What Medical Device Manufacturers Must Know for Compliance in 2025–2030 – April/May 2025

Australia: Unique Device Identification (UDI) Requirements: What Medical Device Manufacturers Must Know for Compliance in 2025–2030 – April/May 2025

  • 2025-04-24 06:13:27

Australia’s implementation of the Unique Device Identification (UDI) system marks a major advancement in medical device traceability and regulatory oversight. This article provides medical device manufacturers with essential guidance on the TGA’s UDI requirements, timelines, and compliance obligations from 2025 through 2030. It also outlines key roles, exemptions, and actionable strategies to support successful market access and patient safety.

More
China: Announcement of the National Medical Products Administration on Further Adjusting and Optimizing Matters Related to the Production of Imported Medical Devices by Domestic Enterprises in China (No. 30 of 2025) – April/May 2025

China: Announcement of the National Medical Products Administration on Further Adjusting and Optimizing Matters Related to the Production of Imported Medical Devices by Domestic Enterprises in China (No. 30 of 2025) – April/May 2025

  • 2025-04-24 07:49:13

The National Medical Products Administration has further adjusted and optimized certain provisions of the Announcement on Matters Concerning the Production of Imported Medical Device Products by Domestic Enterprises in China, originally issued in September 2020.

More
Australia: TGA Updates Application Audit Rules for Medical Devices and IVDs: What Manufacturers Need to Know – February/March 2025

Australia: TGA Updates Application Audit Rules for Medical Devices and IVDs: What Manufacturers Need to Know – February/March 2025

  • 2025-02-21 05:10:50

The Therapeutic Goods Administration (TGA) has updated its application audit guidance for medical devices and in-vitro diagnostics (IVDs), to streamline regulatory processes and focus on high-risk devices. Additionally, the transition from the EU In Vitro Diagnostic Directive (IVDD) to the In Vitro Diagnostic Regulation (IVDR) introduces stricter requirements and extended transition periods for compliance. Medical device manufacturers must ensure thorough documentation and timely submissions to meet these evolving standards.

More
Australia: Understanding the Therapeutic Goods Administration's (TGA) Recall Reforms and the Introduction of the PRAC – January/February 2025

Australia: Understanding the Therapeutic Goods Administration's (TGA) Recall Reforms and the Introduction of the PRAC – January/February 2025

  • 2025-01-22 07:36:15

The Therapeutic Goods Administration (TGA) has introduced the Procedure for Recalls, Product Alerts, and Product Corrections (PRAC) to streamline and enhance the recall processes for therapeutic goods in Australia. By reducing recall categories, simplifying procedural steps, and improving communication, the PRAC aims to foster efficiency and clarity for manufacturers and regulatory consultants. With implementation set for March 2025, stakeholders are encouraged to prepare for these reforms to ensure compliance and contribute to a safer therapeutic goods landscape.

More